Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.
复制标题
DOI：
10.1371/journal.pone.0074820
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Lu S
中科院分区：
文献类型：
--
作者：
Buglione-Corbett R;Pouliot K;Marty-Roix R;West K;Wang S;Lien E;Lu S
近年来，异源初免-加强疫苗已被证明是产生保护性免疫的有效策略，包括针对包括HIV-1在内的多种病原体的体液和细胞介导的免疫应答。临床前和临床研究的先前报告已经显示，与单独使用初免或加强组分相比，病毒载体或DNA疫苗接种随后异源蛋白加强的免疫原性增强。通过这些方法，预期选择包含在蛋白加强组分中的佐剂会影响疫苗的免疫原性和安全性。在本研究中，我们在小鼠模型中检查了几种候选佐剂的血清细胞因子和趋化因子谱：QS-21、Al（OH）3、单磷酰脂质A（MPLA）和ISCOMATRIX™佐剂，在先前测试的五价HIV-1 Env DNA引发蛋白加强制剂DP 6 -001的背景下。我们的数据显示，在DP 6 -001制剂的背景下，候选佐剂的特征在于独特的血清细胞因子和趋化因子谱。这些信息将为未来艾滋病疫苗开发选择佐剂提供有价值的指导，最终目标是增强免疫原性，同时最大限度地减少与使用佐剂相关的反应原性。更重要的是，本文报道的结果将增加关于如何在一般异源引发蛋白加强疫苗接种策略的背景下包括佐剂的知识。
In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of pathogens including HIV-1. Previous reports of preclinical and clinical studies have shown the enhanced immunogenicity of viral vector or DNA vaccination followed by heterologous protein boost, compared to using either prime or boost components alone. With such approaches, the selection of an adjuvant for inclusion in the protein boost component is expected to impact the immunogenicity and safety of a vaccine. In this study, we examined in a mouse model the serum cytokine and chemokine profiles for several candidate adjuvants: QS-21, Al(OH)3, monophosphoryl lipid A (MPLA) and ISCOMATRIX™ adjuvant, in the context of a previously tested pentavalent HIV-1 Env DNA prime-protein boost formulation, DP6-001. Our data revealed that the candidate adjuvants in the context of the DP6-001 formulation are characterized by unique serum cytokine and chemokine profiles. Such information will provide valuable guidance in the selection of an adjuvant for future AIDS vaccine development, with the ultimate goal of enhancing immunogenicity while minimizing reactogenicity associated with the use of an adjuvant. More significantly, results reported here will add to the knowledge on how to include an adjuvant in the context of a heterologous prime-protein boost vaccination strategy in general.
登录
查看更多内容
DOI：
10.1093/infdis/jis367
发表时间：
2012-08-01
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Montefiori DC;Karnasuta C;Huang Y;Ahmed H;Gilbert P;de Souza MS;McLinden R;Tovanabutra S;Laurence-Chenine A;Sanders-Buell E;Moody MA;Bonsignori M;Ochsenbauer C;Kappes J;Tang H;Greene K;Gao H;LaBranche CC;Andrews C;Polonis VR;Rerks-Ngarm S;Pitisuttithum P;Nitayaphan S;Kaewkungwal J;Self SG;Berman PW;Francis D;Sinangil F;Lee C;Tartaglia J;Robb ML;Haynes BF;Michael NL;Kim JH
通讯作者：
Kim JH
影响因子：
56.9
作者：
Mata-Haro, Veronica;Cekic, Caglar;Mitchell, Thomas C.
通讯作者：
Mitchell, Thomas C.
影响因子：
1.5
作者：
Keefer, MC;Wolff, M;Wescott, SL
通讯作者：
Wescott, SL
影响因子：
5.4
作者：
Bansal, Anju;Jackson, Bethany;Goepfert, Paul A.
通讯作者：
Goepfert, Paul A.
影响因子：
158.5
作者：
Mian-McCarthy, Sara;Agnandji, Selidji Todagbe;Vansadia, Preeti
通讯作者：
Vansadia, Preeti